

## **ISHITA DRUGS & INDUSTRIES LIMITED**

### **CODE OF PRACTICES AND PROCEDURES FOR FAIR DISCLOSURE OF UNPUBLISHED PRICE SENSITIVE INFORMATION**

*[As per sub-regulation (1) of regulation 8 of the SEBI (Prohibition of insider Trading) Regulation 2015]*

The Company will adhere to the following so as to ensure fair disclosure of events and occurrences that could impact price of its securities in the market :-

1. Prompt public disclosure of unpublished price sensitive information that would impact price discovery no sooner than credible and concrete information comes into being, in order to make such information generally available.
2. Uniform and universal dissemination of unpublished price sensitive information to avoid selective disclosure.
3. Designation of a senior officer to deal with dissemination of unpublished price sensitive information.
4. Prompt dissemination of unpublished price sensitive information that gets disclosure selectively, inadvertently or otherwise, to make such information generally available.
5. Appropriate and fair response to queries on news reports and requests for verification of market rumors by regulatory authorities.
6. Ensuring that information shared with analysts and research personnel is not unpublished price sensitive information.
7. Developing best practices to make transcripts or records of proceedings of meetings with analysts and other investor relation conferences on the official website to ensure official confirmation and documentation of disclosures made.
8. Handling of all unpublished price sensitive information on a need-to-know basis.



*[Handwritten signature]*